Delivering more for our investors.
Welcome to our Investor Centre. Here you’ll find important information about Avecho Ltd – a compelling investment opportunity – including ASX releases, presentations, latest news and more.
Office: Melbourne, Australia
ASX: AVE
Share Price
Investor highlights
TPM® products commercialised under license:
- Voveran® TPM Gel; Novartis, India
- Instanac® TPM Gel; Themis Medicare
- Vital ET® Biofunctional Ingredient; Ashland
- TPM® (for personal care only); Ashland
Read the latest analyst report from Euroz Hartleys
The Market is Sleeping on this One
Eager to ask a question?
Click here to visit our investor hub and login to join our Q&A.
Investor Resources
Governance
| 2025 Appendix 4G and Corporate Governance Statement | 673KB | |
| 2025 Annual Report | 2MB | |
| Diversity Policy | 248KB | |
| Remuneration and Nomination Committee Charter | 196 KB | |
| Audit and Risk Committee Charter | 156 KB | |
| Whistleblower Policy | 268 KB | |
| Board Charter | 162 KB | |
| Anti Bribery and Corruption Policy | 241 KB | |
| Shareholder Communication Policy | 142 KB | |
| Continuous Disclosure Policy | 226 KB | |
| Code of Conduct | 228 KB | |
| Current Constitution | 1 MB | |
| Remuneration and Nomination Committee Charter | 246 KB | |
| Securities Trading Policy | 127 KB |
Annual General Meeting
| Notice of Annual General Meeting 2026 | 190 KB | |
| Annual Report 31 December 2025 | 1 MB | |
| Employee Incentive Plan | 366 KB |
Investor Communications and Services
Click here to view a summary of Avecho Biotechnology’s Investor Communications and Services.
